Zobrazeno 21 - 30
of 61
pro vyhledávání: '"Chunrong Zhu"'
Autor:
Yunhe Li, Qian Xia, Chunrong Zhu, Weidong Cao, Zhiyang Xia, Xinxin Liu, Bin Xiao, Keyu Chen, Yun Liu, Lei Zhong, Bangxian Tan, Jun Lei, Jiang Zhu
Publikováno v:
Journal of inorganic biochemistry. 236
Myeloperoxidase (MPO), a hallmark of the function and activation of innate immune cells, can act as a 'double-edged sword', contributing to clear infection as well as causing tissue oxidizing damage in various inflammatory diseases. In this study, an
Publikováno v:
Drug Delivery, Vol 28, Iss 1, Pp 2329-2347 (2021)
Drug Delivery
article-version (VoR) Version of Record
Drug Delivery
article-version (VoR) Version of Record
In recent years, the incidence of various types of tumors has gradually increased, and it has also been found that there is a certain correlation between abnormal glucose and lipid metabolism and tumors. Glycolipid metabolism can promote tumor progre
Publikováno v:
Genetic testing and molecular biomarkers. 26(1)
Autor:
Fang, Yuan, Min, Zhang, Chunrong, Zhu, Xiaoyun, Liu, Chenjing, Zhao, Jinfei, Dai, Hua, Dong, Bo, Jiao, Xuguang, Lan, Zhaoxin, Wu
Publikováno v:
Frontiers in Chemistry
Recently, perovskite light-emitting diodes (PeLEDs) have drew widespread attention due to their high efficiencies. However, because of the sensitivity to moisture and oxygen, perovskite luminescent layers are usually prepared in high-purity nitrogen
Autor:
Yanmin Xu, Jinhai Si, Jinfei Dai, Xiaoyun Liu, Jingrui Li, Fang Yuan, Zhaoxin Wu, Hua Dong, Chenjing Zhao, Lihe Yan, Bo Jiao, Chunrong Zhu
Publikováno v:
The journal of physical chemistry letters. 12(48)
The role of triplet states in the interfacial energy transfer in perovskite light-emitting diodes (PeLEDs) has so far not been clarified because of the complex exciton recombination and decay dynamics. This work aims to study this issue and according
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology
Frontiers in Oncology
Colorectal cancer (CRC), a common malignant disease, has the second highest mortality rate among all cancer types. Due to the diversity and heterogeneity of CRC, few effective treatment strategies have been developed in recent years, except for surgi
Background Multiple factors affect the survival time of patients with lung adenocarcinoma (LUAD). Specifically, the therapeutic effect of medicines and the disease recurrence probability differs among patients with the same stage of LUAD. Thus, effec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9281e2bd3ad0630264a947632a73b9e6
https://doi.org/10.21203/rs.3.rs-952541/v1
https://doi.org/10.21203/rs.3.rs-952541/v1
Autor:
Guozhong Wu, Yanhong Gu, Yongqian Shu, Chunrong Zhu, Dongqin Zhu, Liangjun Zhu, Wenyu Zhu, Xue Wu, Wenxiang Shen, Xiangyuan Ma, Xiaoling Tong, Hua Bao, Ruoying Yu, Ping Liu, Jifeng Feng
Publikováno v:
Frontiers in Genetics, Vol 12 (2021)
Frontiers in Genetics
Frontiers in Genetics
Gastrointestinal tract cancers have high incidence and mortality in China, but their molecular characteristics have not been fully investigated. We sequenced 432 tumor samples from the colorectum, stomach, pancreas, gallbladder, and biliary tract to
Autor:
Ke-Yu Chen, Xiao-Ming Zhang, Pan Li, Zhu Jiang, Zhi-Yang Xia, Chengyi Shen, Qian Xia, Tao Cheng, Chunrong Zhu, Lei Zhong, Bin Xiao, Changqiang Wu
Publikováno v:
Journal of medicinal chemistry. 64(13)
Liver-specific contrast agents (CAs) can improve the Magnetic resonance imaging (MRI) detection of focal and diffuse liver lesions by increasing the lesion-to-liver contrast. A novel Mn(II) complex, Mn-BnO-TyrEDTA, with a lipophilic group-modified et
Autor:
Zhichao Jiang, Deng Wei, Yongkun SUN, Jianping Cheng, Wen Zhang, Chunmei Bai, Zuoxing Niu, Chunrong Zhu, Rong Wu, Xiaobing Chen, Yan Zhang, Sheng Li, Yingying Huang, Jianfeng Zhou, Shengbin Shi, Feng Xiong, Yun-Bo Zhao, Liangjun Zhu, Ai-Ping Zhou
Publikováno v:
Journal of Clinical Oncology. 40:3594-3594
3594 Background: Irinotecan and fluorouracil are the most effective drugs in the treatment of metastatic colorectal cancer (mCRC). But XELIRI (irinotecan plus capecitabine) has not been recommended in the 1st-L setting due to the toxicity in the West